Business
CTCs harvested with Parsortix grown in laboratory
CTCs harvested with Parsortix grown in laboratory.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 0019T Angle PLC 09 October 2017 \n\n \n\n\n\n\nFor immediate release\n\n\n 9 October 2017\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nCIRCULATING TUMOUR CELLS, HARVESTED FROM BLOOD, GROWN IN THE LABORATORY FOR THE FIRST TIME\n \nHeinrich Heine University researchers demonstrate that CTCs harvested with ParsortixTM from leukapheresis blood product can be cultured\n \nCultured cells continue to proliferate several months after ParsortixTM harvest\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, today announces that one of its customers has successfully grown circulating tumor cells (CTCs) harvested by ParsortixTM in the laboratory. This is the first time the ability to culture CTCs harvested from blood using ParsortixTM has been published. The CTCs were isolated from diagnostic leukapheresis (DLA) blood product. \n \nThe cells grown in culture harbour genomic abnormalities that confirm their malignant origin. Most of the aberrations were identical to those detected in the uncultured CTCs from the same patient. The cultured cells continue to proliferate several months after ParsortixTM harvest, providing a renewable population of cells for ongoing research and investigation outside the patient.\n \nThe customer, a research group from the Heinrich Heine University, Düsseldorf, Germany, presented their results at Europe's leading circulating tumour cell (CTC) conference, the Third International Advances in Circulating Tumour Cells (ACTC) Symposium (Rhodes, Greece, 4 to 7 October 2017).\n \n \nANGLE Founder and Chief Executive, Andrew Newland, commented:\n\"This is the first time that a patient's CTCs harvested by ParsortixTM have been successfully cultured. The ParsortixTM system's capability to harvest living, viable cancer cells is a key differentiator and we believe this will lead to new avenues of research using ParsortixTM.\" \n \nDr Hans Neubauer, University Hospital and Medical Faculty of the Heinrich-Riche University of Duesseldorf commented: \n\"The use of diagnostic leukapheresis blood product provides larger numbers of CTCs than a normal blood sample. The ParsortixTM system provides an easy solution for harvesting these CTCs keeping the cells alive and undamaged. The workflow we have developed ...